Newbridge Financial Services Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Newbridge Financial Services Group’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Sell	3,061 -417	-12%	-$214K	0.2%	97
2026 Q1	$1.82M	Sell	3,478 -70	-2%	-$33.4K	0.3%	72
2025 Q4	$2.07M	Sell	3,548 -94	-3%	-$48K	0.32%	67
2025 Q3	$1.67M	Buy	3,642 +66	+2%	+$24.6K	0.25%	81
2025 Q2	$1.08M	Sell	3,576 -952	-21%	-$284K	0.18%	98
2025 Q1	$1.5M	Buy	4,528 +325	+8%	+$107K	0.36%	62
2024 Q4	$1.3M	Buy	+4,203	New	+$1.18M	0.33%	67
2024 Q3	–	Sell	-5,894	Closed	-$1.65M	–	928
2024 Q2	$1.65M	Sell	5,894 -5,139	-47%	-$1.22M	0.62%	36
2024 Q1	$2.95M	Buy	+11,033	New	+$2.6M	1.29%	10

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Newbridge Financial Services Group's MDGL Position: Q2 2026 in Review

Newbridge Financial Services Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 12% in Q2 2026, selling an estimated $214K and leaving 3,061 shares worth $1.64M. The position accounts for 0.2% of the portfolio, ranked #97.

Newbridge Financial Services Group first reported a position in MDGL in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.95M in Q1 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Newbridge Financial Services Group held 3,061 shares of Madrigal Pharmaceuticals worth $1.64M as of Q2 2026.
Newbridge Financial Services Group sold 417 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $214K.
Madrigal Pharmaceuticals made up 0.2% of Newbridge Financial Services Group's portfolio in Q2 2026, its #97 holding.
Newbridge Financial Services Group first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Newbridge Financial Services Group's Madrigal Pharmaceuticals position peaked at $2.95M in Q1 2024.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.